Suppr超能文献

一项人类实验室研究,旨在调查喹硫平对每日吸食大麻者戒断和复吸大麻的影响。

A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.

机构信息

Division on Substance Abuse, New York State Psychiatric Institute and Department of Psychiatry, College of Physicians and Surgeons of Columbia University, New York, NY, USA.

出版信息

Addict Biol. 2013 Nov;18(6):993-1002. doi: 10.1111/j.1369-1600.2012.00461.x. Epub 2012 Jun 28.

Abstract

Marijuana withdrawal contributes to the high relapse rates in individuals seeking treatment for marijuana-use disorders. Quetiapine, an atypical antipsychotic, reduces characteristic symptoms of marijuana withdrawal in a variety of psychiatric conditions, including mood lability, sleep disruption and anorexia. This human laboratory study investigated the effectiveness of quetiapine to decrease marijuana withdrawal and relapse to marijuana use in non-treatment-seeking marijuana smokers. Volunteers were maintained on placebo or quetiapine (200 mg/day) in this double-blind, counter-balanced, within-subject study consisting of two 15-day medication phases, the last 8 days of which were in-patient. On the first in-patient day, active marijuana [6.2% delta (9)-tetrahydrocannabinol (THC)] was repeatedly smoked under controlled conditions. For the next 3 days, inactive marijuana (0.0% THC) was available for self-administration (withdrawal). On the subsequent 4 days, active marijuana (6.2% THC) was available for self-administration (relapse). Volunteers (n = 14) who smoked an average of 10 marijuana cigarettes/day, 7 days/week, completed the study. Under placebo, withdrawal was marked by increased subjective ratings of negative mood, decreased sleep quality, and decreased caloric intake and weight loss. Compared with placebo, quetiapine improved sleep quality, increased caloric intake and decreased weight loss. However, quetiapine increased marijuana craving and marijuana self-administration during the relapse phase. These data do not suggest that quetiapine shows promise as a potential treatment for marijuana dependence.

摘要

大麻戒断导致寻求大麻使用障碍治疗的个体复发率居高不下。喹硫平是一种非典型抗精神病药,可减少各种精神疾病中与大麻戒断相关的特征性症状,包括情绪不稳定、睡眠中断和厌食。这项人体实验室研究调查了喹硫平降低非治疗寻求大麻吸食者大麻戒断和复吸大麻的有效性。在这项双盲、平衡、个体内研究中,志愿者接受安慰剂或喹硫平(200mg/天)治疗,该研究包括两个 15 天的药物阶段,最后 8 天为住院期。在第一个住院日,在受控条件下反复吸食活性大麻[6.2%的 Δ(9)-四氢大麻酚(THC)]。接下来的 3 天,可自行摄入非活性大麻(0.0%THC)(戒断)。随后的 4 天,可自行摄入活性大麻(6.2%THC)(复吸)。平均每天吸食 10 支大麻香烟、每周吸食 7 天的 14 名志愿者完成了这项研究。在安慰剂条件下,戒断表现为负面情绪主观评分增加、睡眠质量下降以及热量摄入减少和体重减轻。与安慰剂相比,喹硫平改善了睡眠质量,增加了热量摄入,减少了体重减轻。然而,喹硫平增加了大麻渴求感和复吸阶段的大麻自我摄入。这些数据表明,喹硫平不太可能成为大麻依赖的潜在治疗方法。

相似文献

1
A human laboratory study investigating the effects of quetiapine on marijuana withdrawal and relapse in daily marijuana smokers.
Addict Biol. 2013 Nov;18(6):993-1002. doi: 10.1111/j.1369-1600.2012.00461.x. Epub 2012 Jun 28.
2
Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse.
Psychopharmacology (Berl). 2008 Mar;197(1):157-68. doi: 10.1007/s00213-007-1020-8. Epub 2007 Dec 27.
3
Nabilone decreases marijuana withdrawal and a laboratory measure of marijuana relapse.
Neuropsychopharmacology. 2013 Jul;38(8):1557-65. doi: 10.1038/npp.2013.54. Epub 2013 Feb 26.
4
Marijuana withdrawal in humans: effects of oral THC or divalproex.
Neuropsychopharmacology. 2004 Jan;29(1):158-70. doi: 10.1038/sj.npp.1300310.
5
Effects of zolpidem alone and in combination with nabilone on cannabis withdrawal and a laboratory model of relapse in cannabis users.
Psychopharmacology (Berl). 2016 Jul;233(13):2469-78. doi: 10.1007/s00213-016-4298-6. Epub 2016 Apr 16.
6
Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers.
Addict Biol. 2013 Sep;18(5):872-81. doi: 10.1111/j.1369-1600.2011.00427.x. Epub 2012 Jan 19.
7
Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse.
Psychopharmacology (Berl). 2010 Aug;211(2):233-44. doi: 10.1007/s00213-010-1888-6. Epub 2010 Jun 3.
8
Nefazodone decreases anxiety during marijuana withdrawal in humans.
Psychopharmacology (Berl). 2003 Jan;165(2):157-65. doi: 10.1007/s00213-002-1210-3. Epub 2002 Nov 19.
9
A human laboratory study of the effects of quetiapine on subjective intoxication and alcohol craving.
Psychopharmacology (Berl). 2011 Oct;217(3):341-51. doi: 10.1007/s00213-011-2287-3. Epub 2011 Apr 13.
10
Guanfacine decreases symptoms of cannabis withdrawal in daily cannabis smokers.
Addict Biol. 2019 Jul;24(4):707-716. doi: 10.1111/adb.12621. Epub 2018 Apr 16.

引用本文的文献

2
[Not Available].
CMAJ. 2024 Mar 10;196(9):E303-E321. doi: 10.1503/cmaj.230715-f.
3
Rethinking Substance Use as Social History: Charting a Way Forward.
J Gen Intern Med. 2024 May;39(7):1227-1232. doi: 10.1007/s11606-024-08642-9. Epub 2024 Jan 29.
5
Canadian guideline for the clinical management of high-risk drinking and alcohol use disorder.
CMAJ. 2023 Oct 16;195(40):E1364-E1379. doi: 10.1503/cmaj.230715.
6
Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.
Front Psychiatry. 2023 Jun 26;14:1144276. doi: 10.3389/fpsyt.2023.1144276. eCollection 2023.
7
Treatment of Adolescent Cannabis Use Disorders.
Child Adolesc Psychiatr Clin N Am. 2023 Jan;32(1):141-155. doi: 10.1016/j.chc.2022.07.006. Epub 2022 Oct 22.
10
5HT-2C agonist lorcaserin decreases cannabis self-administration in daily cannabis smokers.
Addict Biol. 2021 Jul;26(4):e12993. doi: 10.1111/adb.12993. Epub 2021 Jan 3.

本文引用的文献

1
The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress.
Drug Alcohol Depend. 2011 Dec 1;119(1-2):123-9. doi: 10.1016/j.drugalcdep.2011.06.003. Epub 2011 Jul 2.
3
Dronabinol for the treatment of cannabis dependence: a randomized, double-blind, placebo-controlled trial.
Drug Alcohol Depend. 2011 Jul 1;116(1-3):142-50. doi: 10.1016/j.drugalcdep.2010.12.010. Epub 2011 Feb 18.
4
Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse.
Psychopharmacology (Berl). 2010 Aug;211(2):233-44. doi: 10.1007/s00213-010-1888-6. Epub 2010 Jun 3.
5
Cannabis withdrawal symptoms in non-treatment-seeking adult cannabis smokers.
Drug Alcohol Depend. 2010 Sep 1;111(1-2):120-7. doi: 10.1016/j.drugalcdep.2010.04.010. Epub 2010 May 26.
6
Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008.
J Forensic Sci. 2010 Sep;55(5):1209-17. doi: 10.1111/j.1556-4029.2010.01441.x.
7
Quetiapine XR: current status for the treatment of major depressive disorder.
Prog Neuropsychopharmacol Biol Psychiatry. 2010 Oct 1;34(7):1165-73. doi: 10.1016/j.pnpbp.2010.03.023. Epub 2010 Mar 20.
8
A randomized trial of contingency management for adolescent marijuana abuse and dependence.
Drug Alcohol Depend. 2009 Dec 1;105(3):240-7. doi: 10.1016/j.drugalcdep.2009.07.009. Epub 2009 Aug 31.
9
Pharmacotherapy for cannabis dependence: how close are we?
CNS Drugs. 2009;23(7):543-53. doi: 10.2165/00023210-200923070-00001.
10
Self-administration of cocaine, cannabis and heroin in the human laboratory: benefits and pitfalls.
Addict Biol. 2009 Jan;14(1):9-21. doi: 10.1111/j.1369-1600.2008.00121.x. Epub 2008 Oct 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验